Last update 01 Nov 2024

TAAR1 x thymosin alpha 1

Last update 01 Nov 2024

Basic Info

Related Targets

TAAR1thymosin alpha 1

Drugs associated with TAAR1 x thymosin alpha 1

CN118085110

Patent Mining

Target

TAAR1 x thymosin alpha 1

Mechanism-

Active Org.

China Pharmaceutical University

Originator Org.

China Pharmaceutical University

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with TAAR1 x thymosin alpha 1

100 Translational Medicine associated with TAAR1 x thymosin alpha 1

0 Patents (Medical) associated with TAAR1 x thymosin alpha 1

Literatures (Medical) associated with TAAR1 x thymosin alpha 1

31 May 2018·Expert Opinion on Biological TherapyQ3 · MEDICINE

Serum thymosin alpha 1 levels in normal and pathological conditions

Q3 · MEDICINE

Review

Author: Buè, Cristina ; Gaziano, Roberta ; Pica, Francesca ; Moroni, Gabriella ; Garaci, Enrico ; Sinibaldi Vallebona, Paola ; Perricone, Roberto ; D’Agostini, Cartesio ; Palamara, Anna Teresa ; Limongi, Dolores ; Tomino, Carlo ; Casalinuovo, Ida Antonia

INTRODUCTIONThymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning.AREAS COVEREDMany clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. The number of diseases that could benefit from Ta1 treatment is increasing. To date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. The sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. These data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation.EXPERT OPINIONLow serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient's baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.

01 Nov 2013·Urologic Oncology: Seminars and Original InvestigationsQ3 · MEDICINE

Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma

Q3 · MEDICINE

Article

Author: Yuh Shyan Tsai ; Tzong Shin Tzai ; Ko Jung Chen ; Ai Li Shiau ; Hsiao Yen Hsieh ; Chao Liang Wu ; Syue Yi Chen ; Yeong Chin Jou ; Hsin Tzu Tsai ; Shan Tair Wang

OBJECTIVESTo determine the plasma levels of thymosin-α1 (TA1) and prothymosin-α (PTMA) proteins in renal cell carcinoma (RCC) or urothelial carcinoma (UC) patients, and explore the potential of these 2 molecules as biomarkers.MATERIALS AND METHODSBlood samples were taken from 50 consecutive patients with RCC, 97 with UC, and 55 with benign urologic diseases before surgery. Their clinical characteristics were obtained from medical record review. Plasma TA1 and PTMA levels were measured using enzyme-linked immunosorbent assay and their correlation with tumor grade, pathologic stage, and survival were explored.RESULTSPlasma TA1 levels were significantly lower in RCC patients than in UC or benign patients, particularly in UC of the renal pelvis patients (P < 0.0001). Plasma PTMA levels were also significantly lower in UC patients compared with RCC patients and benign patients (P < 0.05). Plasma TA1 levels inversely correlated with pathologic stage both in bladder cancer and RCC patients (P = 0.03 and 0.02, respectively). Both plasma TA1 and PTMA did not correlate with tumor grade. Plasma TA1 was a prognostic indicator for progression-free and disease-specific overall survival in bladder cancer patients (P = 0.008 and 0.04, respectively).CONCLUSIONSPlasma TA1 level may be a biomarker for differentiating between UC and RCC. It may also be a prognostic factor for disease progression and disease-specific survival in bladder cancer patients. These findings warrant more studies for validation.

01 Jan 1998·Archivum immunologiae et therapiae experimentalisQ4 · MEDICINE

Epithelial-mesenchymal cell interactions and participation of the neuroendocrine markers in tumor development. Immunohistochemical study.

Q4 · MEDICINE

Article

Author: Kuczkowski, J ; Cynowska, B ; Kamiński, M ; Zółtowska, A ; Kruszewski, W ; Stepiński, J

Existence of the organ stem cell population seems to decide on ability of the tissue to regenerate and, likewise, on carcinogenesis. The source of the organ specific stem cells may be perivascular mesenchyma of thin-walled vascular channels. Our previous study on the breast cancer indicates that the perivascular mesenchyma of thin-walled vessels appears to be source of myoid cells (myofibroblasts) from which cancer cells arise. Similar results have been observed in the cancers of lung, salivary gland and colon, investigated in the current study. The perivascular cells of thin-walled channels are the source of myoid cells with expression of synaptophysin (Syn) and/or chromogranin A (Chg A), and from these cells neoplastic cells could originate. Syn and/or Chg A positive neoplastic cells were particularly well visible in connection with the vascular channels on the peripheries of tumors while other parts of tumors were only weak positive or negative for those neuroendocrine markers. Similarly as in breast cancers, the S100-protein positive dendritic cells with various of distribution were seen, expressing intimate connection with neoplastic cells. The epithelial pearls especially abundant in non-small cell lung carcinomas demonstrated immunohistochemical analogy to Hassall's bodies: they had monocytogenic cell inside and they displayed thymosin alpha 1 (TA1), as well as mucin secretion and minute calcification. Some epithelial cells expressed desmin and Syn. All types of investigated cancers demonstrated TA1. Results of our present study suggest that the perivascular cells have a differentiation defect. Such defect may initiate abnormal stromal environment, commonly observed in neogenesis, however, the presence of thymic growth factors may favor tumor growth.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis